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We describe a new tool, the Physicians’ Practice Assessment Questionnaire (PPAQ), designed
for the global self-assessment of implementation of asthma and COPD guidelines, as deter-
mined by the percentage of patients in whom physicians estimate that they implement guide-
lines key recommendations. Some of its properties were assessed by a group of 47 general
practitioners (GPs), and testeretest data were obtained in repeating the questionnaire at
a 5-week interval without intervention in a sub-group of 28 practitioners. Answers to the
various questions were globally reproducible. The lowest scores (recommendations implemen-
ted in less than 50% of their patients) were: 1) for both asthma and COPD: referral for patient
education, provision of a written action plan and regular assessment of inhaler technique, 2)
for asthma: referral to a specialist for difficult to control asthma or uncertain diagnosis, and 3)
for COPD: assessment of lung function and disability according to specific criteria and referral
to a rehabilitation program. The analysis showed sufficient internal consistency for both ques-
tionnaires (Cronbach alphas 0.7617 for asthma and 0.8317 for COPD). Pearson’s correlations
indicated good testeretest (r Z 0.6421, p Z 0.0002 for asthma; r Z 0.6801, p < 0.0001 for
COPD). In conclusion, the PPAQ is a new tool to assess implementation of asthma and COPD
guidelines; it has the potential to identify care gaps that can be specifically targeted for inter-
vention.
ª 2010 Elsevier Ltd. All rights reserved.8 656 4747; fax: þ1 418 656 4762.
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Physicians’ Practice Assessment Questionnaire 9Introduction
Asthma and Chronic Pulmonary Obstructive Disease (COPD)
are the two most common pulmonary diseases in Canada, as
elsewhere.1,2 Unfortunately, these conditions are still poorly
controlled in a large number of patients and therefore result
in a significant human and socio-economical burden.3e5
Practice guidelines have been developed in the last two
decades to optimize care but their recommendations are
still insufficiently implemented, particularly in primary
care settings.6,7 Various methods have been proposed to
assess if medical practice is in keeping with current
guidelines, including self-assessment questionnaires,
surveys, chart audits or patient questionnaires or outcome
research.8e10 However, to our knowledge, no specific tool
has been developed to globally determine if physicians
have integrated the key recommendations of current
asthma and COPD guidelines recommendations into day-to-
day care.
We describe the Physicians’ Practice Assessment Ques-
tionnaire (PPAQ), a new physician’s self-assessment ques-
tionnaire assessing the implementation of key Canadian
asthma and COPD guidelines recommendations in a group of
Canadian general practitioners, and report the results of
the testeretest of these asthma and COPD questionnaires.
This tool was developed to be used in studies led by the
Canadian Respiratory Guidelines Committee of the Cana-
dian Thoracic Society (CTS) on new strategies to help
increase implementation of Canadian asthma and COPD
guidelines.11Methods
Characteristics of participants
Outofa total of141physicians invited toparticipate, a total of
47 primary care physicians were recruited; 28 (mean medical
practice duration: 28.6 years) completedboth theasthmaand
COPD questionnaires on 2 occasions while an additional 9
practitioners (mean medical practice duration: 21 years)
completed the Asthma-PPAQ and 10, the COPD-PPAQ only
once.Nonewaspreviously aware of thequestions tobeasked.
All participating physicians were practicing Canadian
primary care practitioners with general practices (i.e., not
specialising in particular areas). Physicians invited to
participate were recruited at random from a list of Cana-
dian physicians who had participated in Continuing Medical
Education (CME) initiatives in cardiology, urology or osteo-
porosis within the past 5 years. For those who completed
the questionnaire twice, no specific intervention was con-
ducted between the tests, produced at an average interval
of 5 weeks of each other (testeretest). We did not formally
record the characteristics of the physicians not partici-
pating in this study, but the main reason was a lack of time
for participation.
Production of the PPAQ
This questionnaire was conceived by two of the authors
(LPB and DO) according to the most recent Canadianguidelines12,13 and reviewed by a panel of Canadian asthma
and COPD specialists for their comments and approval.
The Asthma-PPAQ includes 14 key actions suggested by
the most recent Canadian adult asthma consensus guide-
lines,12 which is also in keeping with international guide-
lines.14 For the analyses, the questions were separated into
2 domains (Table 1): 1) Diagnosis and Assessment (Questions
1,4,5,9e11) and 2) Treatment & Follow-up (Questions
2,3,6e8,12e14).
The COPD-PPAQ includes 12 key interventions suggested
by the most recent Canadian COPD consensus guidelines.13
For the analyses, the questions were also separated into 2
domains (Table 2): 1) Diagnosis and Assessment (Questions
1e3,11,12) and 2) Treatment & Follow-up (Questions 4e10).
For each question, the physician was asked to record the
approximate percentage of his/her patients in whom he/she
implemented each guideline recommendation mentioned.
We then obtained a global percent score for each physician,
and also determined the mean score for the whole group of
practitioners for each specific question or domain.
Properties of the PPAQ
The following properties of the questionnaire were evalu-
ated. 1) Testeretest reliability, the ability of the instru-
ment to provide the same results when used repeatedly
under similar conditions and which does not penalize
systematic error attributed to a learning effect that is
a natural phenomenon and not a defect for this procedure,
2) internal consistency, the extent to which different
elements of the tool are measuring the same construct,
determined using Cronbach’s alpha statistics, and 3)
intraclass reliability, the ability of the instrument to
provide the same results when used repeatedly under
similar conditions, taking into account the number of
systematic errors. Cross-sectional construct validity was
not evaluated as there are, to our knowledge, no corre-
sponding evaluation tools to globally assess guidelines
implementation of these key recommendations.
Statistical analysis
This study mostly evaluates “face validity” of the question-
naire. Values are reported as mean  SD. Pearson’s pro-
ductemoment correlation was performed to assess
testeretest reliability. The intraclass correlation (ICC) was
used toassess intrarater reliability. TheStudent’s paired t-test
was performed to compare mean values between 1st and 2nd
questionnaire. The Cronbach’s coefficient alpha estimates
were used to determine the internal consistency of the ques-
tionnaires. The results were considered significant with
p-values 0.05. The data were analyzed using the statistical
package program SAS v9.2 (SAS Institute Inc., Cary, NC).Results
Mean scores
Mean scores for each question were quite different from
one item to another. Low scores (recommendation
Table 1 Asthma Physician Practice Assessment Questionnaire (Asthma-PPAQ)ª.
For what percent of your asthma patients do you currently.
1 Confirm diagnosis by pulmonary function tests (either spirometry
and bronchodilator reversibility or bronchoprovocation)
_____%
2 Provide written referral for asthma education _____%
3 Provide a written action plan for exacerbation management _____%
4 Assess inhaler technique (or refer to asthma educator) at each visit ______%
5 Identify environmental triggers/inducers _____%
6 Provide smoking cessation counseling and/or recommend cessation measures _____%
7 Prescribe an inhaled corticosteroid (ICS) as initial maintenance therapy _____%
8 Prescribe an inhaled ICS and a long-acting beta2-agonist
(LABA) when asthma is not controlled by ICS low dose alone
_____%
9 Check for treatment adherence at each visit _____%
10 Use the Canadian Thoracic Society (CTS) control criteria or the Global
Initiative for Asthma (GINA) guidelines to assess patient’s asthma control
_____%
11 Address patients’ concerns about disease/treatment _____%
12 Refer to a specialist because asthma is difficult to control _____%
13 Refer to a specialist if the asthma diagnosis is uncertain _____%
14 Schedule regular follow-up appointments _____%
10 L.-P. Boulet et al.implemented in less than 50% of patients) were observed
both for asthma (Table 3) and COPD (Table 4) in regard to
referral for patient education, provision of a written
action plan for the management of exacerbations and
regular assessment of inhaler technique. Furthermore, for
asthma, referral to a specialist for difficult to control
asthma or uncertain diagnosis was infrequently imple-
mented. This was also the case for assessment of func-
tional status and disability according to specific Medical
Research Council criteria, as suggested in Canadian
guidelines, and referral to a rehabilitation program.
Testeretest assessment
Answers to the various questions were globally reproducible
although looking at the“testeretest reliability”, better scores
were noted on the second test as indicated by statisticallyTable 2 COPD Physician Practice Assessment Questionnaire (CO
For what percent of your COPD patients do you currently.
1 Confirm diagnosis by pulmonary function tests (i.
bronchodilator with or without lung volumes)
2 Assess level of function & disability (with Modifie
3 Document frequency and severity of COPD exace
4 Prescribe at least one long-acting bronchodilator
as ‘walking slower than people of the same age o
while walking at your own pace on the level’)
5 Prescribe inhaled corticosteroid (ICS)þ long-actin
combination and tiotropium if MRC >3 þ exacerb
6 Provide an exercise prescription to promote regu
7 Refer to pulmonary rehabilitation program if >M
8 Provide written referral for structured patient ed
9 Provide a written action plan for exacerbation m
10 Provide smoking cessation counseling and pharma
11 Assess inhaler/device technique (or refer to COP
12 Refer to specialist if diagnosis is uncertain, if clin
or if home oxygen or surgical options are being csignificantdifferences formany itemsofbothquestionnairese
however these changes were small (Tables 3 and 4).
Testeretest reliability
Pearson’s correlations indicated good testeretest reli-
ability of both the Asthma-PPAQ (r Z 0.6421, p Z 0.0002)
and the COPD-PPAQ (rZ 0.6801, p  0.0001) (Tables 3 and
4, Figs. 1 and 2). For questions related 1) to diagnosis and
assessment, and 2) to treatment, Pearson’s correlations
indicated good testseretest reliability of both the Asthma-
PPAQ (rZ 0.5781, pZ 0.0013 and rZ 0.6500, pZ 0.0002,
respectively) and COPD-PPAQ (r Z 0.6418, p Z 0.0002 and
r Z 0.6944, p  0.0001, respectively).
Intrarater reliability
The ICC indicated good intrarater reliability of both the
Asthma-PPAQ (rZ 0.6184, p  0.0001) and the COPD-PPAQPD-PPAQ)ª.
e., spirometry after _____%
d Medical Research Council (MRC) scale) _____%
rbations _____%
if MRC >3 (where MRC 3 is described
n the level or stopping for breath
_____%
g beta2-agonist (LABA) in
ations (>1/year)
_____%




cological intervention if smoking _____%
D educator) at each visit _____%
ical deterioration is rapid
onsidered
_____%
Table 3 Testeretest and intrarater reliability from Physicians’ Practice Assessment Questionnaire.
Asthma Questionnaire
Physicians’ Practice Assessment Questionnaire Testeretest reliability Intrarater reliability
1st Questionnaire 2nd Questionnaire r p-Value r p-Value
Question #1 50.9  31.3 60.5  30.1 0.7882 <0.0001 0.7948 <0.0001
Question #2 33.8  26.2 32.2  28.4 0.6191 <0.0001 0.6309 <0.0001
Question #3 29.3  27.1 34.2  26.8 0.6819 <0.0001 0.6963 <0.0001
Question #4 28.9  31.3 31.6  29.0 0.5899 0.0010 0.6022 0.0003
Question #5 50.0  29.1 57.7  23.6 0.5234 0.0043 0.4874 0.0045
Question #6 87.3  21.0 91.4  17.4 0.2086 0.2868 0.2236 0.1326
Question #7 73.0  27.9 81.2  19.6 0.5348 0.0049 0.5155 0.0026
Question #8 82.5  22.2 85.2  22.7 0.0557 0.7705 0 1.0000
Question #9 72.9  22.6 77.0  20.7 0.4887 0.0083 0.4893 0.0044
Question #10 63.2  33.1 65.7  27.4 0.4644 0.0128 0.4228 0.0136
Question #11 77.0  25.3 80.0  18.2 0.5040 0.0062 0.4187 0.0144
Question #12 40.3  39.0 43.8  37.5 0.5031 0.0075 0.5194 0.0024
Question #13 49.0  40.8 48.1  37.0 0.5726 0.0018 0.5838 0.0005
Question #14 62.5  34.8 62.5  33.7 0.7179 <0.0001 0.7114 <0.0001
Q1eQ14 Mean 57.2  14.6 60.7  11.0 0.6421 0.0002 0.6184 0.0002
Dx 57.1  18.6 62.1  12.6 0.5781 0.0013 0.5422 0.0015
Rx 57.4  15.8 59.7  14.3 0.6500 0.0002 0.6495 <0.0001
Questions related to diagnosis and assessment Dx:1,4,5,9e11.
Questions related to treatment Rx:2,3,6e8,12e14.
Physicians’ Practice Assessment Questionnaire 11(rZ 0.6771, p  0.0001) (Tables 3 and 4, Figs. 1 and 2). For
questions related to diagnosis and assessment and to treat-
ment, the ICC indicated good intrarater reliability for both
Asthma-PPAQ (r Z 0.5422, p Z 0.0015 and r Z 0.6495,
p  0.0001, respectively) and COPD-PPAQ (r Z 0.6529,
p  0.0001 and rZ 0.6851, p  0.0001, respectively).Table 4 Testeretest and intrarater reliability from Physicians’
COPD Questionnaire
Physicians’ Practice Assessment Questionnaire
1st Questionnaire 2nd Questionnaire
Question #1 71.1  32.2 74.8  28.0
Question #2 42.0  36.9 44.6  34.9
Question #3 58.6  30.9 62.9  27.8
Question #4 70.0  28.6 75.7  21.2
Question #5 69.3  30.4 80.2  18.1
Question #6 55.0  34.9 63.4  32.0
Question #7 34.0  30.8 36.4  24.9
Question #8 18.6  22.1 27.0  24.0
Question #9 32.5  33.1 34.5  27.6
Question #10 93.8  14.7 91.4  15.4
Question #11 29.8  32.0 39.8  30.1
Question #12 65.4  38.1 53.5  36.1
Q1eQ12 Mean 53.018.7 57.015.0
Dx 53.421.2 55.019.8
Rx 52.819.0 58.414.6
Questions related to diagnosis and assessment Dx:1e3,11,12. Item 12
an assessment item.
*Questions related to treatment Rx:4e10.Internal consistency
Cronbach’s alpha coefficient indicated good internal
consistency for both the Asthma-PPAQ (0.7617) and the
COPD-PPAQ (0.8317). For questions related to diagnosis and
assessment and to treatment, Cronbach’s alpha coefficient
indicated good internal consistency for Asthma-PPAQPractice Assessment Questionnaire.
Testeretest reliability Intrarater reliability
r p-Value r p-Value
0.8039 <0.0001 0.7676 <0.0001
0.6213 0.0004 0.6164 0.0002
0.4705 0.0115 0.4308 0.0120
0.3259 0.0972 0.3321 0.0491
0.6607 0.0002 0.5264 0.0021
0.4802 0.0097 0.4903 0.0043
0.7719 <0.0001 0.7573 <0.0001
0.5452 0.0027 0.5605 0.0010
0.6837 <0.0001 0.6870 <0.0001
0.0491 0.8039 0.0864 0.3357
0.7869 <0.0001 0.7925 <0.0001
0.4555 0.0170 0.4589 0.0076
0.6801 <0.0001 0.6771 <0.0001
0.6418 0.0002 0.6529 <0.0001
0.6944 <0.0001 0.6851 <0.0001
includes a treatment component but has been mainly considered
Figure 1 Testeretest % scores for asthma questionnaire.
12 L.-P. Boulet et al.(0.7145 and 0.6172 respectively) and COPD-PPAQ (0.5988
and 0.7808 respectively).
Relationships between scores for COPD vs asthma
In regard to categorical scores for COPD vs asthma, those
related to treatment were poorly correlated (R: 0.21) while
the mean score for items related to diagnosis was more
consistent (R: 0.72). For global COPD vs asthma score, it
was intermediate (R: 0.56).
Discussion
Despite the recent decades’ progress in the understanding
and treatment of asthma and COPD, these conditions are
still associated with a high morbidity and health-care
use.3e5 Numerous national and international guidelines
have been developed in the last decades to improve the
management of these diseases but their implementation
into care is still deficient. There is, however, a need to
develop better knowledge transfer strategies and assess if
they are effective.
The CTS Canadian Respiratory Guidelines Committee
recently reorganised its respiratory guidelines production,Figure 2 Testeretest % scores for COPD questionnaire.dissemination, implementation and assessment of their
effectiveness to improve respiratory care.11 This group also
aimed at developing new tools to assess how physicians
implement current practice guidelines.
Previous studies on the efficacy of CME programs
included as outcomes, selected physicians’ behaviours or
patient-related outcomes, but there is still a need to
develop instruments that would globally assess how physi-
cians report implementing the main recommendations of
current guidelines.8 The present tool uses a consensually
selected number of key recommendations from the last
Canadian asthma and COPD guidelines for which physicians
estimated the percentage of patients in whom they follow
such recommendation. The study showed that this tool
globally provides reproducible values, the changes
observed being very small and unlikely to be clinically
significant. The differences between the two assessments
were more marked in the COPD patients’ assessment and it
would be of interest to further explore why there were such
differences compared to the asthma questionnaire.
Furthermore, a next step will also be to evaluate how an
effective intervention could improve current care using this
questionnaire.8,15,16
In regard to weaknesses of our study, self-report by
physicians may not always correspond to reality and it will
certainly be useful in the future to validate those results in
a subset of physicians using chart audits. This last method
however also has some weaknesses, as physicians do not
always record their actions following patient encoun-
ters.17,18 In regard to the relatively short time interval
between the two questionnaires, we cannot exclude the
possibility of overestimating the reproducibility of the
questionnaire due to a memory effect, although it is
unlikely. Furthermore, as stated above, we need to eval-
uate more adequately responsiveness to change of the
global PPAQ score and a next step will be to evaluate how
an effective intervention could improve current care, when
assessed with this questionnaire.8,15,16 Hopefully, this
questionnaire may eventually become a useful instrument
to assess how effective are the interventions aiming to
change the clinician’s behaviour. Finally, we recognize that
some of the criteria tested in the COPD questionnaire are
not necessarily in keeping with other guidelines, but as
mentioned previously, the goal of this study was to look at
the implementation of the Canadian guidelines. We
encourage other guideline developers who wish to evaluate
success of implementation of selected key management
recommendations (which may vary slightly from country to
country) to modify the physician assessment questionnaires
accordingly.
In regard to the various domains evaluated by the PPAQs,
the analysis suggests that both PPAQs may be useful ques-
tionnaires, with interesting properties. In this regard, they
both indicate good internal consistency, testeretest reli-
ability and intrarater reliability. This suggests that the
PPAQs can contribute to the evaluation of current practice
and its conformity to guidelines, but likely could be useful
to assess if an intervention improves uptake of the chosen
recommendations and translation into current practice.
Furthermore, it is possible that if repeated over time, this
questionnaire may act as a guide and incentive for the
physician to develop means to improve his/her practice.
Committee. Laval University Chair on to knowledge
Transfer, Prevention and Education in Respiratory and
Cardiovascular Health. Chair of the Global Initiative
for Asthma (GINA) Dissemination and Implementation
Committee.
H. Devlin:
No real or apparent conflicts.
D. O’Donnell:
Advisory Boards: AstraZeneca, Altana, GlaxoSmithK-
line, Boehringer Ingelheim, Pfizer, Nycomed and
Novartis.
Lecture fees: GlaxoSmithKline, Boehringer Ingelheim,
Pfizer, and Novartis.
ponsorship for investigator-generated research:
GlaxoSmithKline, Boehringer Ingelheim, Pfizer.
Organisational: Past-Chair of the Canadian Thoracic
Society COPD Guidelines Committee
Physicians’ Practice Assessment Questionnaire 13We therefore think that such instrument may be of
interest both as an assessment and self-examination of
implementation of current guidelines recommendations by
physicians. From such questionnaire, interventions to fill
the care gaps between current and what is considered
optimal care could be better targeted. It will be interesting
in the future to compare the performance of various
caregivers including pneumologists, allergists, pediatricians
and general practitioners in regard to such questionnaires.
In regard to the discrepancies observed in current
practice, compared to the current guidelines, they are in
keeping with those previously reported.6,19,20 Some are
common to both asthma and COPD, such as referral for
patient education, provision of a written action plan and
regular assessment of inhaler technique. We previously
showed that objective measures to confirm the diagnosis of
asthma are particularly neglected and probably explain the
observed overdiagnosis of asthma, in addition to sometimes
inadequate assessment of asthma control.19,21 With respect
to COPD our results are consistent with those of Bourbeau
et al. who reported discrepancies between recommended
treatment and current care in regard to pharmacological
treatment and spirometric confirmation of diagnosis, but
particularly referral for pulmonary rehabilitation.20
In conclusion, we describe a new physician’s self-
assessment tool for the global assessment of Asthma and
COPD guidelines implementation and provide an evaluation
of its properties. Such instruments are needed to better
assess current practice and the effects of the often
demanding and costly interventions provided to improve
chronic diseases care. The PPAQ properties suggest that it is
a valid and potentially useful tool in this regard.
Acknowledgments
We are grateful to Serge Simard for his help with data
analysis.
Supported by: GlaxoSmithKline Canada.Disclosure of potential conflicts of interest
LP Boulet:
Advisory Boards: AstraZeneca, Altana, GlaxoSmithK-
line, Merck Frosst and Novartis.
Lecture fees: 3M, Altana, AstraZeneca, Glax-
oSmithKline, Merck Frosst and Novartis.
Sponsorship for investigator-generated research:
AstraZeneca, GSK, Merck Frosst, Schering.
esearch funding for participating in multicenter
studies: 3M, Altana, AsthmaTx, AstraZeneca, Boeh-
ringer-Ingelheim, Dynavax, Genentech, Glax-
oSmithKline, IVAX, MedImmune, Merck Frosst,
Novartis, Roche, Schering, Topigen, Wyeth.
Support for the production of educational materials:
AstraZeneca, GlaxoSmithKline and Merck Frosst.
Governmental: Adviser for the Conseil du Me´dicament
du Que´bec.
Organisational: Chair of the Canadian Thoracic
Society Guidelines Dissemination and ImplementationReferences
1. Canadian Institute for Health Information, Canadian Lung
Association, Health Canada, Statistics Canada. Respiratory
disease in Canada. 1st ed. Ottawa: Health Canada; 2001. p.
1e102.
2. Bousquet J, Dahl R, Khaltaev N. Global alliance against chronic
respiratory diseases. Eur Respir J 2007;29:233e9.
3. Chapman KR, Ernst P, Grenville A, Dewland P, Zimmerman S.
Control of asthma in Canada: failure to achieve guideline
targets. Can Respir J 2001 March;8(Suppl. A):35Ae40A.
4. Godtfredsen NS, Lam TH, Hansel TT, Leon ME, Gray N,
Dresler C, et al. COPD-related morbidity and mortality after
smoking cessation: status of the evidence. Eur Respir J 2008;
32:844e53.
5. Fournier M, Tonnel AB, Housset B, et al. SCOPE. Economic
burden of COPD: the SCOPE study. Rev Mal Respir 2005;22:
247e55.
6. Boulet LP, Becker A, Bowie D, et al. Implementing practice
guidelines: a workshop on guidelines dissemination and
implementation with a focus on asthma and COPD. Can Respir J
2006;13(Suppl. A):5e47.
7. Jin R, Choi BC, Chan BT, et al. Physician asthma management
practices in Canada. Can Respir J 2000;7:456e65.
8. Grol R, Grimshaw J. From best evidence to best practice:
effective implementation of change in patients’ care. Lancet
2003;362:1225e30.
9. Davis D. Clinical practice guidelines and the translation of
knowledge: the science of continuing medical education. CMAJ
2000;163:1278e9.
10. Gross PA, Greenfield S, Cretin S, et al. Optimal methods for
guideline implementation: conclusions from Leeds Castle
meeting. Med Care 2001;39:II85e92.
11. Boulet LP, McIvor RA, Marciniuk D, Canadian Thoracic Society
Respiratory Guidelines Committee. Respiratory guidelines
implementation in Canada. Can Respir J 2007;14:329e30.
12. Lemie`re C, Bai T, Balter M, et al on behalf of the Canadian
Adult Consensus Group of the Canadian Thoracic Society. Adult
asthma consensus guidelines update 2003. Can Respir J 2004
May;11(Suppl. A):9Ae18A.
13. O’Donnell D, Hernandez P, Kaplan A, et al. Canadian Thoracic
Society recommendations for management of chronic
obstructive pulmonary disease e 2008 update e highlights for
primary care. Can Respir J 2008;15(Suppl. A):1Ae8A.
14 L.-P. Boulet et al.14. Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for
asthma management and prevention: GINA executive
summary. Eur Respir J 2008;31:143e78.
15. Davis DA,ThomsonMA,OxmanAD,HaynesRB.Changingphysician
performance. A systematic review of the effect of continuing
medical education strategies. JAMA 1995;274:700e5.
16. Boulet LP. Improving knowledge transfer on chronic respiratory
diseases: a Canadian perspective. How to translate recent
advances in respiratory diseases into day-to-day care. J Nutr
Health Aging 2008;12:758se63s.
17. Grimshaw JM, Thomas RE, MacLennan G, et al. Effectiveness
and efficiency of guideline dissemination and implementation
strategies. Health Technol Assess (Winchester, England) 2004;
8 [iiieiiv].
18. Jamtvedt G, Young JM, Kristoffersen DT, Thomson O’Brien MA,
Oxman AD. Audit and feedback: effects on professionalpractice and health care outcomes. Cochrane Database Syst
Rev; 2003.
19. Jin R, Choi BC, Chan BT, McRae L, Li F, Cicutto L, Boulet LP,
Mitchell I, Beveridge R, Leith E. Physician asthma management
practices in Canada. Can Respir J 2000;7:456e65.
20. Bourbeau J, Sebaldt RJ, Day A, Bouchard J, Kaplan A,
Hernandez P, Rouleau M, Petrie A, Foster G, Thabane L,
Haddon J, Scalera A. Practice patterns in the management of
chronic obstructive pulmonary disease in primary practice: the
CAGE study. Can Respir J 2008;15:13e9.
21. Aaron SD, Vandemheen KL, Boulet LP, McIvor RA,
Fitzgerald JM, Hernandez P, Lemiere C, Sharma S, Field SK,
Alvarez GG, Dales RE, Doucette S, Fergusson D, Canadian
respiratory Clinical research Consortium. Overdiagnosis of
asthma in obese and nonobese adults. CMAJ 2008;179:
1121e31.
